Unique ID issued by UMIN | UMIN000050063 |
---|---|
Receipt number | R000056929 |
Scientific Title | Pharmacokinetic study by single intake of the test food (pilot study) |
Date of disclosure of the study information | 2023/01/21 |
Last modified on | 2023/04/13 09:53:01 |
Pharmacokinetic study by single intake of the test food (pilot study)
Pharmacokinetic study by single intake of the test food (pilot study)
Pharmacokinetic study by single intake of the test food (pilot study)
Pharmacokinetic study by single intake of the test food (pilot study)
Japan |
Healthy adults
Not applicable | Adult |
Others
NO
To investigate the pharmacokinetics of active ingredients during a single intake of the test food
PK,PD
The time to maximum concentration (Tmax) of active ingredients
Blood concentration of active ingredients at each time point after ingestion of the test food
Area Under the Curve(AUC) and Maximum serum concentration(Cmax) of active ingredients
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Food |
Intake of test food
20 | years-old | <= |
35 | years-old | > |
Male
1) Age: 20-34, healthy male
2) BMI: 18.5 kg/m2-24.9 kg/m2
3) Subjects who giving informed consent.
1) Subjects with a serious medical history, or with a history of disorders of the digestive system, circulatory system (e.g., heart failure), endocrine system, etc. Subjects who have been judged to be inappropriate for the study by the principal investigator.
2) Subjects who have a history of gastrointestinal resection surgery, excluding appendectomy.
3) Subjects who are currently taking medication or being treated by a physician.
4) Subjects who must be scheduled to receive medical treatment or medication during the study period.
5) Subjects who plan to consume health foods or supplements other than the food under study after consent.
6) Subjects who are unable to consume the test food due to preference or allergy. Subjects who may have allergies related to the test food.
7) Heavy drinkers of alcohol and heavy smokers.
8) Subjects who have difficulty in taking blood samples.
9) Subjects who donated blood over 200mL in the past 4 weeks or over 400mL in the past 12 weeks.
10) Subjects who currently or will be participating in another clinical research study during the study period.
11) Subjects who have irregular sleep or eating habits due to night work or insomnia.
12) Subjects who are engaged in strenuous physical activity.
13) Subjects judged as unsuitable for the study by the responsible doctor for other reasons.
25
1st name | Sayuri |
Middle name | |
Last name | Matsuoka |
FANCL Corporation
Research Institute
244-0806
12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa, Japan
045-820-3449
matsuoka@fancl.co.jp
1st name | Reiko |
Middle name | |
Last name | Naito |
Kenkoin Medical Corporation Foundation
Kenkoin Clinic
104-0061
6-7-4 Ginza, Chuo-ku, Tokyo, Japan
03-3573-1153
reiko-naito@kenkoin.jp
Other
Other
Profit organization
Kenkoin Medical Corporation Foundation Clinical Research Ethics Committee
6-7-4 Ginza, Chuo-ku, Tokyo, Japan
03-3573-1153
isamu-yanase@kenkoin.jp
NO
2023 | Year | 01 | Month | 21 | Day |
Unpublished
Completed
2022 | Year | 12 | Month | 24 | Day |
2022 | Year | 12 | Month | 24 | Day |
2023 | Year | 01 | Month | 21 | Day |
2023 | Year | 03 | Month | 31 | Day |
2023 | Year | 01 | Month | 18 | Day |
2023 | Year | 04 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056929